2020
Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series
Ma H, Cheng B, Montanari F, Lue JK, Deng C, Marchi E, Connor O, Sawas A. Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series. Therapeutic Advances In Hematology 2020, 11: 2040620720947340. PMID: 33062232, PMCID: PMC7534065, DOI: 10.1177/2040620720947340.Peer-Reviewed Original ResearchAutologous stem cell transplantClassical Hodgkin lymphomaR cHLRefractory classical Hodgkin lymphomaStable diseasePartial responseComplete responseHodgkin's lymphomaPatient populationToxicity profileHigher disease control rateMedian progression-free survivalAlanine transaminase elevationClinical benefit rateLeast equivalent efficacyDisease control rateProgression-free survivalRetrospective case seriesStem cell transplantTolerable toxicity profileFavorable safety profileFavorable toxicity profileContinuous lenalidomideCreatinine elevationTransaminase elevation
2014
Relapsed Hodgkin Lymphoma: Management Strategies
Montanari F, Diefenbach C. Relapsed Hodgkin Lymphoma: Management Strategies. Current Hematologic Malignancy Reports 2014, 9: 284-293. PMID: 24942298, PMCID: PMC4909353, DOI: 10.1007/s11899-014-0220-7.Peer-Reviewed Original ResearchConceptsStem cell transplantAutologous stem cell transplantHigh-dose chemotherapyCell transplantHodgkin's lymphomaAllogeneic hematopoietic stem cell transplantHematopoietic stem cell transplantChemotherapy-refractory diseaseRelapsed Hodgkin lymphomaTransient disease controlElderly patient populationFirst-line therapyManagement of patientsBrentuximab vedotinDose chemotherapyRefractory diseaseComplete responseConventional therapyPatient populationNovel therapiesNew agentsPatientsDisease controlTransplantTherapy